Zim Laboratories Limited has announced a proposed inter-se transfer of equity shares among its promoters. Dr. Anwar Daud will acquire 80,000 equity shares, representing 0.15% of the company's paid-up equity share capital, from Mr. Zulfiquar Kamal. This transaction is being conducted off-market and qualifies for exemption under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition is set to take place any time after 4 working days from the date of intimation, which is June 4, 2026, meaning it can occur on or after June 11, 2026. The acquisition price will not exceed the limits provided in the proviso to Regulation 10(1)(a) of the SEBI SAST Regulations. The weighted average market price for the preceding 60 trading days was ₹86.39. Following this transaction, the shareholding of Dr. Anwar Daud (as part of the promoter group) will increase to 1,63,41,632 shares, constituting 25.05% of the total paid-up equity share capital. The seller, Mr. Zulfiquar Kamal, will continue to hold 33,33,320 shares, representing 24.90% of the total share capital. Both parties confirm compliance with Chapter V of the SEBI (SAST) Regulations.
